2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult
PAPER

5459 Impact of time of day of bispecific antibody administration on clinical outcomes in relapsed/refractory aggressive B-cell lymphoma: A real-world analysis from the realbite consortium

Adrienne N. Nedved, PharmD, MPA, Yucai Wang, MD, PhD2, Stephanie Franco, MD3, Natalie S Grover, MD4, Xi Yang, MD5, Yasmin H Karimi, MD6, Emma Williams, MD7, Priyanka A. Pophali, MD8, Sally Jones, MD9, Aditi Saha, MD10, Jun Chih Wang, MD11, Jose Sandoval-Sus I, MD12, Tenley Schwarz13, Matthew Schwede, MD, MS14, Rodolfo Garza Morales, MD15, Javier L. Munoz, MD, MBA16, Emma Gray, MD17, Emily Ayers, MD18, Kelsey Baron, MD19, Boyu Hu, MD20, Saloni Savani, MD21, Cyrus Khan, MD22, Xiancheng Wu, MD23, Stephen Douglas Smith, MD24, Paolo Fabrizio Caimi, MD25, Brian Hill, MD, PhD26, Taylor R. Brooks, MD27
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
4 University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
5 University of Michigan, Ann Arbor, Michigan, United States
6 University of Michigan, Ann Arbor, Michigan, United States
7 University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
8 University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
9 University of Alabama at Birmingham, Birmingham, Alabama, United States
10 University of Alabama at Birmingham, Birmingham, Alabama, United States
11 Moffitt Cancer Center, Pembroke Pines, Florida, United States
12 Moffitt Cancer Center, Pembroke Pines, Florida, United States
13 Swedish Cancer Institute, Seattle, Washington, United States
14 Swedish Cancer Institute, Seattle, Washington, United States
15 Mayo Clinic, Phoenix, Arizona, United States
16 Mayo Clinic, Phoenix, Arizona, United States
17 University of Virginia, Charlottesville, Virginia, United States
18 University of Virginia, Charlottesville, Virginia, United States
19 University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States
20 University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States
21 Allegheny Health Network, Pittsburgh, Pennsylvania, United States
22 UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
23 Fred Hutchinson Cancer Center, Seattle, Washington, United States
24 Fred Hutchinson Cancer Center, Seattle, Washington, United States
25 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
26 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
27 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States

Introduction: T-cell trafficking and antitumor immunity has been shown to vary with circadian rhythms, and, in some studies, time of day of chimeric antigen receptor (CAR) T-cell infusion has been associated with efficacy and altered inflammatory cytokine profiles among patients with large B-cell lymphoma (LBCL). Bispecific antibodies (BsAbs) redirect endogenous T cells with repeated dosing, enabling a within-patient analysis of administration timing. Whether time of day of BsAb administration affects outcomes is unknown. We evaluated whether treatment timing is associated with efficacy and toxicity among individuals with LBCL.

Methods: We performed a retrospective study including 13 US centers evaluating patient with relapsed or refractory aggressive LBCL receiving commercially available epcoritamab (epco)-, glofitamab (glofit)-, or mosunetuzumab (mosun)-containing regimens (monotherapy or in combination with other agents) between 2023 and 2026. The primary exposure was the time of BsAb infusion for each dose delivered prior to the first response assessment. Patients with documented 24-hour administration times were included for analyses, with analyses restricted to patients with a documented first full-dose time and complete follow-up. Time of day was modeled continuously, as a circadian sine/cosine function, and dichotomized (early <12:00 vs late ≥12:00). Primary end points were progression-free survival (PFS) and overall survival (OS). Cytokine release syndrome (CRS) was defined according to consensus criteria. PFS and OS were analyzed by Cox regression, unadjusted and adjusted according to bispecific agent, age, ECOG PS, prior lines, prior CAR T, combination therapy, recent prior therapy, LDH, and center. Grade ≥2 CRS per dose was analyzed by mixed-effects logistic regression using a within-between (Mundlak) decomposition isolating a within-patient effect, adjusting for administered dose and baseline factors; a three-level model tested between-center effects, and a grade-1-only endpoint tested temperature-related ascertainment. Overall response rate (ORR) and complete response (CR) rate were assessed per treating clinical according to Lugano 2014 criteria.

Results: Of 423 treated patients, 360 with a documented first full-dose time and follow-up were analyzed for efficacy; toxicity analyses included 1,388 cycle-1 doses in 406 patients. Median age was 69 (IQR 59-77); DLBCL NOS 71.2%, high-grade B-cell lymphoma 13.7%, and other (e.g., mantle cell lymphoma, Burkitt, and PTLD) 15.1%. Patients received a median 2 prior lines of therapy (range 1-10). Regimens were epco-, glofit-, and mosun-based in 40.2%, 53.9%, and 5.9%, respectively (19.9% in combination). Median first full-dose time was 12:25. In unadjusted analyses, later administration was associated with worse PFS and OS, and were fully attenuated after adjustment (PFS 1.04/hour, 0.98-1.10, p=0.16; OS 1.05, 0.98-1.12, p=0.16; early-vs-late PFS HR 1.12 [95% CI 0.82–1.52], p=0.49 and OS 1.21 [95% CI 0.83–1.76], p=0.32); similarly, modeling administration time as a cyclic 24-hour (sine/cosine) rhythm likewise showed no association (PFS p=0.63, OS p=0.66). Response rates were not different after adjustment (adjusted ORR 61% vs 59%; CR 37% vs 35%; adjusted OR for later administration 0.94, p=0.81 and 0.90, p=0.69, respectively). The within-patient odds of grade ≥2 CRS increased with later administration (OR 1.22/hour, 1.02-1.44, p=0.025), as did the between-patient odds (1.35, 1.00-1.81, p=0.047), not fully accounted for by between-center differences (0.72, 0.43-1.19, p=0.20). In a grade-1-only endpoint, the within-patient association was null (1.04, 0.91-1.17, p=0.59).

Conclusions: In this real-world cohort, time of day of BsAb administration was not independently associated with PFS, OS, or response. In contrast, a within-patient analysis accounting for time-invariant patient confounding showed increased risk of grade ≥2 CRS with later administration. These findings highlight the importance of rigorous adjustment on potential confounders when evaluating chronotherapy in oncology. The association of time of day administration with CRS is consistent with circadian modulation of T-cell-mediated toxicity and is hypothesis-generating, warranting prospective evaluation of administration timing and toxicity mitigation. Additional analyses of inflammatory biomarkers, competing risks, and prespecified sensitivity analyses will be presented.

Adrienne N. Nedved, PharmD, MPA: No relevant conflicts of interest to declare.